Merck, a leading science and technology company, today inaugurated its € 170 million Nantong pharmaceutical plant, which is dedicated to producing high-quality pharmaceuticals on China's Essential Drug List. At the inauguration ceremony, Merck also announced a further investment of around € 80 million in a Life Science Center

Divergent perceptions and attitudes about obesity may jeopardise obesity management outcomes, according to findings from the Awareness, Care & Treatment In Obesity Management (ACTION) study. The findings were presented at Obesity Week 2016, the fourth annual combined congress of the American Society for Metabolic and Bariatric Surgery and The Obesity Society.

Pfizer China announced today that it has received approval from the Chinese Food and Drug Administration (CFDA) to market its pneumococcal 13-valent conjugate vaccine, Prevenar 13®, in China for active immunization for the prevention of invasive diseases (including bacteremic pneumonia, meningitis, septicemia, and bacteremia) caused by Streptococcus pneumoniae (S. Pneumoniae) serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in infants and children aged 6 weeks to 15 months.

Merck, a leading science and technology company, and the American Cancer Society (ACS) today released a report that shows all four of the top causes of cancer deaths in women worldwide are mostly preventable or can often be detected early, when treatment is more successful.

Novartis has been awarded the prestigious 2016 Prix Galien USA Award for Best Biotechnology Product for Cosentyx® (secukinumab), as well as the Prix Galien Foundation "Discovery of the Decade" Award for Best Pharmaceutical Product for the drug Gleevec® (imatinib mesylate). The awards were presented at a ceremony in New York City.

Abbott is among the best science-based companies to work for in the world. For the 13th consecutive year, the journal Science recognized Abbott on its Top Employers list, evaluated on 23 characteristics including financial strength, easy adaptation to change and a having a research-driven environment.

Following the recent update on clinicaltrials.gov, AstraZeneca confirms that the US FDA has placed a partial clinical hold on the enrolment of new patients with head and neck squamous cell carcinoma (HNSCC) in clinical trials of durvalumab as monotherapy and in combination with tremelimumab or other potential medicines.